We are live on ! Find out more
HBIO icon

Harvard Bioscience

69 hedge funds and large institutions have $60.6M invested in Harvard Bioscience in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

27% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 22

7% less capital invested

Capital invested by funds: $65.1M → $60.6M (-$4.49M)

15% less funds holding

Funds holding: 8169 (-12)

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

Holders
69
Holders Change
-12
Holders Change %
-14.81%
% of All Funds
1.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
3
Increased
28
Reduced
22
Closed
15
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
DIA
51
Denver Investment Advisors
Colorado
$43K -$3.17K -114 -7%
Goldman Sachs
52
Goldman Sachs
New York
$42K -$45.1K -1,623 -51%
State Street
53
State Street
Massachusetts
$41K
AIM
54
Acrospire Investment Management
Illinois
$35K +$18.4K +662 +109%
Walleye Trading
55
Walleye Trading
New York
$35K +$21.7K +780 +150%
MFW
56
Meristem Family Wealth
Minnesota
$34K
Two Sigma Investments
57
Two Sigma Investments
New York
$30K -$278 -10 -0.9%
MFS
58
MSI Financial Services
Massachusetts
$27K
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$27K +$13.9K +500 +100%
NFA
60
Nationwide Fund Advisors
Ohio
$24K
UBS Group
61
UBS Group
Switzerland
$19K +$8.08K +291 +71%
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
$17K -$7.97K -287 -31%
BIM
63
BlackRock Investment Management
Delaware
$15K
TRCT
64
Tower Research Capital (TRC)
New York
$12K -$12.2K -438 -49%
EARNEST Partners
65
EARNEST Partners
Georgia
$7K
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K
Wells Fargo
67
Wells Fargo
California
$5K +$5.55K +200 New
LTFS
68
Ladenburg Thalmann Financial Services
Florida
$1K
BNP Paribas Financial Markets
69
BNP Paribas Financial Markets
France
$5
CCM
70
Cadence Capital Management
Massachusetts
-$783K -27,381 Closed
TA
71
Teton Advisors
New York
-$447K -15,639 Closed
PP
72
Paloma Partners
Connecticut
-$359K -12,529 Closed
LCM
73
Laurion Capital Management
New York
-$271K -9,487 Closed
SO
74
STRS Ohio
Ohio
-$254K -8,884 Closed
CCMH
75
Cornerstone Capital Management Holdings
New York
-$194K -6,775 Closed

HBIO Hedge Fund Activity: Q3 2016 in Review

69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2016, worth a combined $60.6M — down 6.9% from $65.1M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of HBIO and 3 opened new positions — a net loss of 12 holders — while 22 trimmed existing stakes and 28 added.

The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.36M. The largest seller was Polar Asset Management Partners, cutting an estimated $1.64M.

  • 69 institutional investors held Harvard Bioscience (HBIO) as of Q3 2016, down from 81 in Q2 2016.
  • Funds reported $60.6M of Harvard Bioscience stock for Q3 2016, down 6.9% quarter-over-quarter.
  • 3 funds opened new Harvard Bioscience positions in Q3 2016 and 15 closed out, a net change of -12 holders.
  • The largest Harvard Bioscience buyer in Q3 2016 was Kennedy Capital Management, an estimated $1.36M added.
  • The largest Harvard Bioscience seller in Q3 2016 was Polar Asset Management Partners, an estimated $1.64M sold.

Based on aggregated 13F filings for Q3 2016.